• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

    9/14/23 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email

    REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023.

    "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 2024, where we hope to demonstrate the safety and proof-of-concept of our oral therapy for diabetic macular edema," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "As we look ahead to these upcoming milestones, we remain committed to our mission of delivering transformative therapies to patients with devastating metabolic diseases."

    Corporate and Clinical Highlights

    • RZ358, monoclonal antibody for the treatment of congenital hyperinsulinism (HI)
      • Following the successful Phase 2b RIZE study of RZ358 in congenital HI, which demonstrated that RZ358 safely and substantially improved hypoglycemia, the Company plans to initiate sunRIZE, a pivotal Phase 3 clinical study of RZ358, in Europe and other geographies outside the US in Q4 2023. Topline results from the sunRIZE study are expected in the first half of 2025.
    • RZ402, oral plasma kallikrein inhibitor to treat diabetic macular edema (DME)
      • In December 2022, Rezolute announced the initiation of a Phase 2 study of RZ402 in patients with DME. This is a multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naïve to or have received limited anti-VEGF injections. Study enrollment is ongoing, and the Company anticipates topline results from this study in the first quarter of 2024.

    Fourth Quarter and Full Year Fiscal 2023 Financial Results

    • Cash and cash equivalents totaled $16.0 million and investments in marketable debt securities totaled $102.3 million as of June 30, 2023.



    • Research and development (R&D) expenses were $10.9 million for the fourth quarter of fiscal 2023, compared to $8.6 million for the same period in fiscal 2022. Full fiscal year 2023 R&D expenses were $43.8 million, compared to $32.5 million in fiscal year 2022. The increase from fiscal year 2022 to fiscal year 2023 was primarily due to increased expenditures in clinical trial activities, manufacturing costs and higher personnel-related expenses, which included employee compensation and stock-based compensation.



    • General and administrative (G&A) expenses were $3.3 million for the fourth quarter of fiscal 2023, compared to $2.7 million for the same period in fiscal 2022. Full fiscal year 2023 G&A expenses were $12.2 million, compared to $9.4 million in fiscal year 2022. The increase from fiscal year 2022 to fiscal year 2023 was primarily due to higher personnel-related expenses, including employee compensation and stock-based compensation.



    • Net loss was $12.7 million for the fourth quarter of fiscal 2023, compared to $9.4 million for the same period in fiscal 2022. Full year fiscal 2023 net loss was $51.8 million compared to net loss of $41.1 million for the fiscal year 2022.

    About Rezolute, Inc.

    Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician, and advocate voices are integrated in the Company's drug development process, enabling Rezolute to boldly address a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients' lives. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter or LinkedIn.

    Forward-Looking Statements

    The information provided herein contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. The "forward-looking statements" include, but are not limited to, statements regarding receiving results from the Phase 2 study of RZ402 in the first quarter of 2024, the ability of RZ358 to treat congenital hyperinsulinism, the timing of the release topline results from sunRIZE, and our ability to meet trial enrollment goals.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Rezolute's current beliefs, expectations and assumptions regarding the future of its businesses, results of and timing of clinical trials, financial condition and results of operations, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

    Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Rezolute's control. Rezolute's actual results including the timing and results of clinical trials may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause Rezolute's actual results including the timing and results of clinical trials to differ materially from those indicated in the forward-looking statements are discussed or identified in Rezolute's filings made with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Rezolute in this information are based only on information currently available to Rezolute and speak only as of the date on which the statement is made. Rezolute undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise except as required by applicable law.

    Investor:

    Kimberly Minarovich

    Argot Partners

    [email protected]

    212-600-1902



    Media:

    [email protected]



             
    Rezolute, Inc.
    Condensed Consolidated Financial Statements Data
    (in thousands, except per share data)
             
      Three Months Ended Year Ended
      June 30, June 30,
       2023   2022   2023   2022 
    Condensed Consolidated Statements of Operations Data:        
             
    Operating expenses:        
    Research and development $10,933  $8,574  $43,813  $32,486 
    General and administrative  3,305   2,725   12,177   9,357 
    Total operating expenses  14,238   11,299   55,990   41,843 
    Loss from operations  (14,238)  (11,299)  (55,990)  (41,843)
    Non-operating income (expense), net  1,510   1,876   4,203   783 
    Net loss $(12,728) $(9,423) $(51,787) $(41,060)
             
    Net loss per common share        
    Basic $(0.25) $(0.30) $(1.01) $(2.26)
    Diluted $(0.25) $(0.37) $(1.01) $(2.32)
             
    Weighted average number of common shares outstanding:        
    Basic  51,410   31,429   51,188   18,197 
    Diluted  51,410   36,302   51,188   19,487 
             
          June 30, June 30,
           2023   2022 
             
    Condensed Consolidated Balance Sheets Data:        
    Cash and cash equivalents     $16,036  $150,410 
    Investments in marketable debt securities      102,330   - 
    Working capital      99,710   149,642 
    Total assets      123,721   152,420 
    Accumulated deficit      (260,984)  (209,198)
    Total stockholders' equity      123,721   149,471 
             



    Primary Logo

    Get the next $RZLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 6:59:50 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 10:04:23 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/13/24 5:31:40 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

      Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.  BTD for ersodetug was granted based on clinical trial data across the overall program and a re

      5/5/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: The Citizens JMP Life Sciences Conference Date: May 7-8, 2025 Event: H.C. Wainwright BioConnect Investor Conference Date: May 20, 2025 Event: Craig-Hallum Institutional Investor Conference Date: May 28, 2025 Event: Jefferies Global Healthcare Conference Date: June 3-5, 2025 Management will be participating in one-on-one investor meetings thro

      5/1/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute, Inc. Announces Closing of Underwritten Offering

      NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the "Offering") of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock a

      4/25/25 4:30:35 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Financials

    Live finance-specific insights

    See more

    $RZLT
    SEC Filings

    See more
    • Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

      Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

      2/13/24 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports First Quarter Fiscal 2024 Results

      REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o

      11/13/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

      REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20

      9/14/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/28/25 5:00:44 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:22:25 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rezolute Inc.

      424B5 - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:20:21 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

      REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

      3/26/25 7:30:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon

      1/24/24 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute's Oral PKI for Treatment of DME

      REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute's investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME). Rezolute also announced the appointment of ophthalmology expert and key opinion leader, Dr. Rajat Agrawal, MD, MS, as Vice President, Clinical Development to lead the RZ402 clinical development program. "The Phase 1b study will evaluate the

      8/10/21 7:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care